Barriers to clinical trial enrollment

Part I of a two-part series

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

According to the National Cancer Institute (NCI), 1,735,350 people were newly diagnosed with cancer in 2018. Of those, 65% are expected to achieve remission from their cancer 1.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Growing up in inner-city Detroit, Otis Brawley had a thriving community made up of his parents, Jesuit priests, friends, and neighbors encouraging him that he could do anything he put his mind to. 
On Feb. 3, the House of Representatives passed the Senate Amendment to H.R. 7148, the Consolidated Appropriations Act, 2026, by a vote of 217 to 214. Later that day, President Donald Trump signed the bill into law, officially ending the brief partial government shutdown that began on Jan. 31. 
Daniel Wall, BSc
Research administrator, Marshfield Clinic
Stephanie Engelien, RN, MSN
Oncology research nurse, Marshfield Clinic
Adedayo A. Onitilo, MD, PhD, MSCR, FACP
Director, Oncology/Hematology
and Radiation Oncology Service Line; Department chair, Oncology/Hematology, Marshfield Clinic

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login